Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
BET inhibitors
BET protein
cancer
clinical trials
combination therapy
hematological malignancies
solid tumors
targeted therapy
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
21
11
2018
accepted:
04
01
2019
entrez:
26
3
2019
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
Histone lysine acetylation is critical in regulating transcription. Dysregulation of this process results in aberrant gene expression in various diseases, including cancer. The bromodomain, present in several proteins, recognizes promotor lysine acetylation and recruits other transcription factors. The bromodomain extra-terminal (BET) family of proteins consists of four conserved mammalian members that regulate transcription of oncogenes such as
Identifiants
pubmed: 30906568
doi: 10.4155/fsoa-2018-0115
pmc: PMC6426170
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
FSO372Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
Science. 2002 Jul 5;297(5578):102-4
pubmed: 12098700
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Transcription. 2013 Jan-Feb;4(1):13-7
pubmed: 23131666
Nat Rev Cancer. 2012 Jun 22;12(7):465-77
pubmed: 22722403
Blood. 2014 Jan 30;123(5):697-705
pubmed: 24335499
Cancer Med. 2013 Dec;2(6):826-35
pubmed: 24403256
Oncotarget. 2017 Jan 31;8(5):7598-7613
pubmed: 27935867
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70
pubmed: 25049379
Oncogene. 2014 Mar 27;33(13):1736-1742
pubmed: 23604113
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Oncotarget. 2017 Mar 21;8(12):19478-19490
pubmed: 28061448
Cancer Res. 2013 Jun 1;73(11):3336-46
pubmed: 23576556
Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Haematologica. 2012 Aug;97(8):1246-54
pubmed: 22331265
Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a018713
pubmed: 24691964
Cell Death Dis. 2014 Feb 06;5:e1047
pubmed: 24503539
Mol Cell Biol. 2002 Jun;22(11):3794-802
pubmed: 11997514
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
Oncogene. 2016 Sep 8;35(36):4689-97
pubmed: 26804177
Semin Cancer Biol. 2006 Aug;16(4):318-30
pubmed: 16934487
Epigenetics. 2014 Apr;9(4):611-20
pubmed: 24496381
EMBO Rep. 2003 May;4(5):484-90
pubmed: 12776737
Cancer Discov. 2016 May;6(5):492-500
pubmed: 26976114
Clin Cancer Res. 2015 Jan 1;21(1):77-86
pubmed: 25370471
Ann Rheum Dis. 2016 Feb;75(2):422-9
pubmed: 25467295
Cancer Res. 2017 May 1;77(9):2476-2487
pubmed: 28209615
Nature. 2011 Oct 02;478(7370):529-33
pubmed: 21964340
J Neuropathol Exp Neurol. 2015 Aug;74(8):778-90
pubmed: 26115193
Brief Funct Genomics. 2013 May;12(3):219-30
pubmed: 23543289
Oncotarget. 2013 Nov;4(11):2080-95
pubmed: 24231268
Br J Cancer. 2014 Mar 4;110(5):1189-98
pubmed: 24518598
Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9
pubmed: 24272870
Cell Rep. 2014 Sep 25;8(6):1919-1929
pubmed: 25242322
Mol Cell Biol. 2011 Jul;31(13):2641-52
pubmed: 21555454
Oncotarget. 2013 Dec;4(12):2419-29
pubmed: 24293458
Cell Res. 2014 Jul;24(7):809-19
pubmed: 24874954
Oncogene. 1998 Nov 12;17(19):2463-72
pubmed: 9824157
J Clin Invest. 2016 Feb;126(2):639-52
pubmed: 26752646
Bioessays. 1998 Aug;20(8):615-26
pubmed: 9780836
Science. 2009 Aug 14;325(5942):834-40
pubmed: 19608861
Blood. 2002 Jan 1;99(1):121-9
pubmed: 11756161
Chem Biol. 2006 Jan;13(1):81-90
pubmed: 16426974
Mol Cancer Ther. 2002 Aug;1(10):841-9
pubmed: 12492117
Cancer Chemother Pharmacol. 2014 Nov;74(5):1057-64
pubmed: 25217392
PLoS One. 2013 Aug 23;8(8):e72967
pubmed: 24009722
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16669-74
pubmed: 21949397
Oncogene. 2018 May;37(21):2850-2862
pubmed: 29511348
Int J Cancer. 2017 Sep 1;141(5):967-976
pubmed: 28542846
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
J Biol Chem. 2014 Dec 19;289(51):35494-502
pubmed: 25355313
Oncotarget. 2014 May 15;5(9):2355-71
pubmed: 24796395
Nature. 1999 Jun 3;399(6735):491-6
pubmed: 10365964
Nature. 2011 Aug 03;478(7370):524-8
pubmed: 21814200
Mol Cancer Ther. 2014 May;13(5):1194-205
pubmed: 24435449
Leukemia. 2014 Feb;28(2):311-20
pubmed: 24220271
Drug Discov Today Technol. 2016 Mar;19:45-50
pubmed: 27769357
Oncotarget. 2015 Jul 10;6(19):17698-712
pubmed: 25989842
Oncotarget. 2017 May 29;8(31):51621-51629
pubmed: 28881673
Br J Haematol. 2017 Sep;178(6):936-948
pubmed: 28653353
Oncotarget. 2015 Mar 20;6(8):5501-16
pubmed: 25849938
Clin Cancer Res. 2015 Apr 1;21(7):1628-38
pubmed: 25623213
Curr Opin Struct Biol. 2011 Dec;21(6):735-43
pubmed: 21872466
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Oncotarget. 2015 Feb 10;6(4):2407-20
pubmed: 25537515
ACS Chem Biol. 2013 Nov 15;8(11):2360-5
pubmed: 24007471
Oncotarget. 2015 Oct 20;6(32):33623-35
pubmed: 26378038
Cell Rep. 2017 Feb 28;18(9):2162-2174
pubmed: 28249162
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33
pubmed: 10618400
Oncotarget. 2014 May 30;5(10):3168-72
pubmed: 24930440
Cell Rep. 2015 Apr 21;11(3):390-404
pubmed: 25865888
Mol Oncol. 2012 Dec;6(6):579-89
pubmed: 22963873
J Biol Chem. 2009 Dec 25;284(52):36547-36556
pubmed: 19828451
EMBO Rep. 2003 Jun;4(6):575-80
pubmed: 12776177
Autophagy. 2017 Apr 3;13(4):761-762
pubmed: 28118076
Haematologica. 2017 Oct;102(10):1776-1784
pubmed: 28751557
Lipid Insights. 2013 Dec 22;6:47-54
pubmed: 25278768
Cell Death Dis. 2018 Feb 22;9(3):315
pubmed: 29472532
J Biol Chem. 2012 Nov 9;287(46):38755-66
pubmed: 23027873
Expert Opin Ther Pat. 2014 Feb;24(2):185-99
pubmed: 24261714
Leukemia. 2014 Oct;28(10):2049-59
pubmed: 24721791
Clin Cancer Res. 2014 Feb 15;20(4):912-25
pubmed: 24297863
Clin Cancer Res. 2013 Apr 1;19(7):1748-59
pubmed: 23403638
Oncotarget. 2018 May 29;9(41):26491-26506
pubmed: 29899872
Cell Res. 2014 May;24(5):513-31
pubmed: 24662484
Leukemia. 2017 Oct;31(10):2037-2047
pubmed: 28074072
Blood. 2012 Oct 4;120(14):2843-52
pubmed: 22904298
Lancet Haematol. 2016 Apr;3(4):e186-95
pubmed: 27063977
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9
pubmed: 24248379
Lancet Haematol. 2016 Apr;3(4):e196-204
pubmed: 27063978
Nat Cell Biol. 2011 Oct 09;13(11):1295-304
pubmed: 21983563
Expert Rev Mol Med. 2011 Sep 13;13:e29
pubmed: 21933453
Mol Cancer Ther. 2014 Oct;13(10):2315-27
pubmed: 25053825
Cancer Res. 2002 Jun 15;62(12):3507-10
pubmed: 12067996
Cancer Cell. 2015 Jun 8;27(6):837-51
pubmed: 26058079
Nat Rev Drug Discov. 2014 May;13(5):337-56
pubmed: 24751816
Sci Rep. 2015 Mar 25;5:9489
pubmed: 25807524
Chem Biol. 2011 Apr 22;18(4):531-41
pubmed: 21513889
J Med Chem. 2012 Sep 13;55(17):7342-5
pubmed: 22928775
Cell. 2013 Aug 1;154(3):569-82
pubmed: 23911322
Biochim Biophys Acta. 2014 Aug;1839(8):676-85
pubmed: 24686119
Clin Cancer Res. 2017 Jun 1;23(11):2781-2794
pubmed: 27864418
Chem Res Toxicol. 2018 May 21;31(5):302-307
pubmed: 29600711
Nat Genet. 2002 Jun;31(2):141-9
pubmed: 11992124
Cancer Res. 2017 Jun 1;77(11):2976-2989
pubmed: 28416490